Three Peptides, One Metabolic Pathway: The Energy Bundle

Most compounds researched for metabolic effects attack the problem from a single angle. Push more energy through the mitochondria, or block the enzyme that tells fat cells to keep growing, or trigger fat breakdown directly — pick one mechanism and hope it’s enough. The Metabolism & Energy Research Bundle is built on a different premise: what happens when you study three separate, non-overlapping mechanisms at once, each one addressing a different stage of the same metabolic pathway?

MOTS-c, 5-Amino-1MQ, and AOD-9604 don’t compete for the same receptor or enzyme. One is a mitochondrial-derived peptide that appears to switch on the cell’s own energy-sensing machinery. One blocks a single enzyme that adipocytes rely on to keep storing fat. One is a fragment of human growth hormone, engineered to isolate its fat-mobilising effect while leaving out the parts of GH biology that make dosing it directly complicated. Individually, each has its own research story. Together, they cover mitochondrial output, fat storage, and fat release — three distinct control points in the same system.

In brief:

• MOTS-c is a 16-amino-acid peptide encoded inside mitochondrial DNA itself, discovered in 2015 by researchers at the University of Southern California and shown to activate AMPK, the cell’s master energy-sensing pathway.
• 5-Amino-1MQ is a small-molecule inhibitor of nicotinamide N-methyltransferase (NNMT), an enzyme adipocytes upregulate as they accumulate fat — blocking it is associated with reduced fat mass in diet-induced obese mice without a corresponding drop in food intake.
• AOD-9604 is a 16-amino-acid fragment derived from the C-terminal region of human growth hormone, isolated specifically because it retains GH’s fat-mobilising activity without activating GH’s growth-promoting or blood-glucose-raising effects.
• A 2025 study in Frontiers in Physiology found MOTS-c restored mitochondrial respiration in a model of the type 2 diabetic heart, extending its research base well beyond the original 2015 metabolic findings.
• All three compounds are supplied by Crown Peptides with a batch-specific certificate of analysis confirming HPLC purity and mass spectrometry identity for every vial in the bundle.

Crown Peptides supplies MOTS-c, 5-Amino-1MQ, and AOD-9604 for laboratory research use only — none of the three is approved for human use, and nothing in this article should be read as a claim otherwise.

Why Bundle Three Unrelated Mechanisms Together

It’s a reasonable question: what actually connects a mitochondrial peptide, an enzyme inhibitor, and a growth hormone fragment? The answer is the pathway they sit on, not the molecule class they belong to. Energy metabolism research tends to break down into three broad control points — how much energy a cell’s mitochondria can actually produce, how readily fat cells store incoming energy as triglyceride, and how readily that stored triglyceride gets released and oxidised when it’s needed. Most single compounds studied in this space sit on one of those three points. Rarely does a single molecule meaningfully touch all three at once.

That’s the logic behind studying MOTS-c, 5-Amino-1MQ, and AOD-9604 as a set rather than in isolation. MOTS-c’s research base centres on mitochondrial output and the cellular signalling that follows from it. 5-Amino-1MQ’s research centres on what happens inside the adipocyte as it decides whether to keep growing. AOD-9604’s research centres on the release step — mobilising the fat that’s already stored. None of the three papers behind these compounds test them in combination with each other, so it’s worth being direct about that: the bundle’s rationale is mechanistic complementarity established through each compound’s separate literature, not a published combination study. That’s a meaningful distinction, and researchers designing protocols around the bundle should treat the three compounds as parallel single-agent research questions rather than assume synergy that hasn’t been directly tested.

There’s also a practical reason bundles like this one have become a common way researchers organise their own protocols, beyond the mechanistic logic. Sourcing three compounds from three different research areas — a mitochondrial peptide field that barely existed a decade ago, an enzymology literature built around NAD+ and methylation biology, and a growth-hormone-fragment story with roots in 1990s endocrinology — normally means piecing together separate orders from separate points in a catalogue. Grouping them by the pathway they collectively describe turns three unrelated literature searches into one coherent research question: what happens when mitochondrial output, fat storage, and fat release are all under investigation in the same protocol.

The Peptide Your Own Mitochondria Already Make

Every other peptide in Crown Peptides’ catalogue is synthesised to mimic something the body produces from nuclear DNA. MOTS-c is different in a way that made it a genuine surprise when it was first characterised: it’s encoded within the mitochondrial genome itself, inside a region of the 12S ribosomal RNA gene that researchers had, until fairly recently, assumed was purely structural. That a functional, secreted peptide hormone could be hiding inside what looked like housekeeping mitochondrial RNA was not something the field expected.

The discovery came from Changhan Lee, Pinchas Cohen, and colleagues at the University of Southern California, published in Cell Metabolism in 2015. Their central finding was that MOTS-c administration in mice prevented diet-induced obesity and age-dependent insulin resistance, and that it did so through a specific, identifiable mechanism: activation of AMPK, the enzyme widely described as the cell’s master metabolic switch. AMPK activation is the same broad signalling event triggered by exercise and by caloric restriction — it’s the cellular signal that tells a cell to prioritise energy production and glucose uptake over storage. MOTS-c produced measurable improvements in glucose tolerance and insulin sensitivity in the treated mice, and the effect held up whether the peptide was given to young or metabolically stressed, older animals.

What makes MOTS-c mechanistically distinct from most metabolic peptides is where it appears to act. Follow-up work from the same broader research programme found that under metabolic stress, MOTS-c doesn’t just act in the cytoplasm — it translocates to the nucleus, where it’s been shown to regulate the expression of nuclear genes involved in antioxidant response and cellular stress adaptation. That’s an unusual property for a peptide of mitochondrial origin: a signal that originates in one genome and travels to directly influence gene expression governed by the other. It positions MOTS-c less as a simple hormone and more as a communication line between the mitochondria and the nucleus, reporting on the cell’s energetic state and prompting a coordinated response.

Part of a Wider Family Researchers Are Still Mapping

MOTS-c isn’t the only peptide researchers have found hidden inside mitochondrial DNA — it’s simply the best-characterised member of a small but growing family known collectively as mitochondrial-derived peptides, or MDPs. Humanin, the first MDP identified, was found encoded within the mitochondrial 16S rRNA gene and has its own separate research literature focused on cytoprotection and neurodegeneration. The small-humanin-like peptides, abbreviated SHLPs, followed as a further set of candidates identified through similar genomic scanning of mitochondrial DNA regions once assumed to be purely structural. That MOTS-c sits within a broader, still-expanding family matters for how seriously the field takes it: it isn’t an isolated curiosity but one confirmed example of what appears to be a genuine, previously overlooked layer of mitochondrial signalling biology, with implications for how researchers think about mitochondrial DNA’s coding capacity more broadly.

That broader context also explains why MOTS-c attracted rapid research interest once it was characterised. A peptide hormone encoded in the genome researchers had spent decades treating as a fixed, well-mapped set of thirteen protein-coding genes for the electron transport chain represented a genuine gap in the field’s understanding — and gaps like that tend to draw sustained follow-up investigation, which is exactly what’s happened with MOTS-c’s expanding literature in the years since 2015.

What the Newest Cardiac Research Adds to the Picture

The oxidative-stress and insulin-sensitivity story from 2015 is the foundation of MOTS-c’s research base, but it isn’t the end of it. A 2025 study published in Frontiers in Physiology examined MOTS-c’s effect specifically on mitochondrial respiration in a model of the type 2 diabetic heart — cardiac tissue where mitochondrial dysfunction is a well-established feature of the disease process. The researchers reported that MOTS-c administration restored aspects of mitochondrial respiratory function that had been impaired by the diabetic state, extending the peptide’s research relevance from general metabolic regulation into a specific, disease-relevant tissue context.

That’s the kind of finding that matters for how a research programme develops: a decade-old mechanistic hypothesis about AMPK activation and mitochondrial support getting tested in an increasingly specific, disease-relevant model, and holding up. It doesn’t turn MOTS-c into a treatment for diabetic cardiomyopathy — no completed human trial exists for that or any other indication — but it does mean the compound’s research trajectory is still actively expanding into new, mechanistically coherent territory a full decade after its initial characterisation, which is a meaningfully different position than a peptide whose evidence base has gone quiet.

Blocking the Enzyme That Tells Fat Cells to Keep Growing

5-Amino-1MQ takes a completely different approach to the same broad research area, and it isn’t technically a peptide at all — it’s a small molecule, specifically a selective, cell-permeable inhibitor of an enzyme called nicotinamide N-methyltransferase, or NNMT. It’s included in the bundle because its research profile and its role in the same metabolic pathway make it a natural fit alongside MOTS-c and AOD-9604, even though its chemistry is different from the two peptides it’s sold alongside.

NNMT is an enzyme that methylates nicotinamide using SAM (S-adenosylmethionine) as the methyl donor, and it turns out to matter a great deal in adipose tissue. As fat cells expand and become metabolically stressed — the process researchers call adipocyte hypertrophy — they tend to upregulate NNMT expression substantially. That matters because the NNMT reaction consumes both NAD+ precursor material and SAM, two molecules central to cellular energy metabolism and methylation biology respectively. High NNMT activity effectively diverts these resources away from processes that would otherwise support a leaner, more metabolically active cellular state, reinforcing the fat-storing phenotype rather than opposing it.

The foundational study behind 5-Amino-1MQ specifically, published in Biochemical Pharmacology by Neelakantan and colleagues, introduced it as a selective, membrane-permeable NNMT inhibitor and tested it in diet-induced obese mice. The compound reversed high-fat-diet-induced obesity in the treated animals — notably, without the mice eating less, which is the detail that made the finding interesting rather than simply another appetite suppressant. The effect appeared to work through the metabolic consequences of NNMT inhibition itself: restored NAD+ and SAM availability, and downstream changes in how adipocytes handle incoming energy, rather than through reduced caloric intake.

What Happens When You Combine NNMT Inhibition With Diet

A follow-up study published in Scientific Reports examined what happens when NNMT inhibition is combined with a reduced-calorie diet in diet-induced obese mice, rather than tested against an unrestricted diet alone. The combination produced a distinct shift in gut microbiome composition compared to either intervention alone, pointing to metabolic effects that extend beyond adipose tissue itself and into the broader systems that influence energy balance. It’s a reminder that NNMT’s role in metabolism isn’t confined to fat cells in isolation — the enzyme sits at a genuine metabolic crossroads, and inhibiting it appears to have consequences that ripple outward into connected systems, which is exactly the kind of finding that keeps a mechanism interesting for further research rather than closing the book on it.

Why NAD+ and SAM Availability Matters Beyond Fat Cells

It’s worth spending a moment on why NNMT’s resource-consuming reaction is interesting to researchers well beyond the adipose-tissue literature specifically. NAD+ is a cofactor required by sirtuins, a family of enzymes closely tied to cellular stress resistance and the broader biology of metabolic ageing — many of the compounds researched for longevity-adjacent outcomes work, at least in part, by supporting NAD+ availability. SAM, meanwhile, is the cell’s primary methyl-group donor, feeding into DNA methylation, histone modification, and a wide range of other methylation-dependent processes that influence gene expression. An enzyme that consumes both of these resources at meaningfully elevated rates in expanding fat tissue represents a genuine metabolic drain, and that’s precisely why NNMT inhibition research has expanded well beyond its original obesity framing into broader metabolic-health and ageing-adjacent research questions over the years since 5-Amino-1MQ was first characterised.

The Growth Hormone Fragment Built to Do One Job

AOD-9604’s origin story explains almost everything about why it’s studied the way it is. Human growth hormone does a great many things in the body — stimulates linear growth in children, influences blood glucose regulation, and, among its effects in adults, promotes lipolysis, the breakdown of stored fat for energy. Researchers at Monash University in Australia, working under Professor Frank Ng in the 1990s, set out to answer a specific question: could the fat-mobilising piece of that activity be isolated from the rest of growth hormone’s biology, producing a research compound that triggers lipolysis without also driving the growth-promoting and glucose-elevating effects that make full-length hGH more complicated to research in a metabolic context?

The answer was AOD-9604 — a 16-amino-acid fragment derived from the C-terminal region of hGH, corresponding to amino acids 177 to 191 of the parent hormone with an additional tyrosine residue added at the N-terminus. That C-terminal region had already been identified as hGH’s lipolytic domain — the specific stretch of the molecule responsible for its fat-mobilising activity — well before AOD-9604 itself was developed as a stabilised, synthesisable fragment built around it.

The foundational research, published by Ng and colleagues at Monash University, described AOD-9604 as a synthetic lipolytic domain of human growth hormone and characterised its metabolic effects directly. A related study, examining chronic treatment with either full-length human growth hormone or the modified C-terminal fragment in obese mice, found increased fat oxidation and measurable weight loss in the treated animals — evidence that the isolated fragment retained meaningful lipolytic activity despite lacking the rest of the hGH molecule’s structure. AOD-9604 went on to be tested in Phase II human obesity trials in the early 2000s, run by the Australian biotechnology company then developing it, making it one of the relatively small number of research peptides in this catalogue with any completed human trial data behind it at all — though it’s worth being precise about what that means: those trials examined AOD-9604 as an investigational obesity treatment, and the compound has not received a human-use approval from the FDA, MHRA, or any equivalent regulator. It remains, today, a research compound rather than an approved medicine.

What made those Phase II trials notable within the wider peptide field was less the efficacy data on its own and more what the trials reportedly found on the safety side: because AOD-9604 was engineered specifically to exclude the growth-promoting, IGF-1-elevating region of the hGH molecule, the developers’ rationale from the outset was that it should carry a different risk profile than full-length growth hormone use — without the acromegaly-associated growth effects or the insulin-resistance concerns that accompany chronic hGH exposure. That was the entire premise the fragment-engineering approach was built to test, and it’s a big part of why AOD-9604 remains one of the more frequently referenced examples of rational peptide-fragment design in the research literature, independent of where its obesity-treatment development programme ultimately landed.

Why the Fragment Approach Matters

The value of the fragment strategy becomes clearer once you consider what full-length growth hormone does that AOD-9604 was specifically designed not to do. Systemic hGH administration raises IGF-1 levels and can meaningfully affect blood glucose regulation, both of which complicate its use as a research tool focused purely on fat metabolism — effects on growth signalling and glucose handling become confounding variables in a study meant to isolate lipolysis specifically. By truncating hGH down to its C-terminal lipolytic domain, AOD-9604’s research profile stays focused on the fat-mobilisation question its developers set out to answer, without the growth-axis and glucose-axis effects layered on top. That’s the entire logic of a fragment peptide: keep the piece of the parent molecule’s biology you want to study, and engineer out the rest.

How Each Compound Is Actually Made

The three compounds in this bundle come from genuinely different manufacturing disciplines, which is easy to overlook when they’re grouped together as a single research bundle. MOTS-c and AOD-9604, at 16 amino acids each, are built using standard solid-phase peptide synthesis — assembling the chain one residue at a time on a resin support, then cleaving and purifying the finished peptide. AOD-9604 carries an added manufacturing wrinkle relative to a simple linear chain: its sequence includes two cysteine residues, positioned so that the finished peptide is expected to form an internal disulfide bridge, mirroring the structure of that same region within the parent hGH molecule. Confirming that the disulfide bond has actually formed correctly — rather than the peptide sitting in an unfolded, reduced state — is a specific verification step that a simple mass check alone doesn’t fully resolve, which is one of the reasons mass spectrometry identity confirmation matters as much as purity data for a peptide with this particular structural feature.

5-Amino-1MQ follows an entirely different production route, since it’s a small organic molecule rather than a peptide chain. It’s produced through conventional organic synthesis, building the quinolinium ring system and its substituents through standard synthetic chemistry rather than sequential amino-acid coupling. That’s a meaningfully simpler synthesis pathway in some respects, but it introduces its own verification priorities — confirming the correct salt form, ring substitution pattern, and absence of synthesis by-products through techniques like HPLC and mass spectrometry, the same broad verification toolkit used for the peptides in the bundle, applied to a different kind of molecule.

Where the Research Goes From Here

Each compound in this bundle sits at a different point on the research-to-clinic pipeline, and that’s worth stating plainly rather than glossing over. AOD-9604 has the most clinical-stage history, having already gone through Phase II human trials, even though that programme has not resulted in a regulatory approval to date. MOTS-c’s evidence base is expanding steadily from its 2015 foundation into increasingly specific disease models, most recently cardiac tissue, but remains at the rodent and cell-culture stage without a published human trial. 5-Amino-1MQ sits earliest on that pipeline of the three, with its strongest data still confined to diet-induced obese mouse models, though its mechanism has proven robust enough across multiple independent follow-up studies to keep attracting continued research investment.

Taken together, the direction of travel across all three research programmes points the same way: toward more specific, more mechanistically detailed investigation rather than away from it. That’s a meaningfully different trajectory than a compound whose early promising findings simply failed to replicate or attract follow-up interest, and it’s part of why all three remain active, frequently cited subjects in the metabolic-research peptide literature.

Storage and Handling Across the Bundle

All three compounds in the bundle follow the storage fundamentals that apply across lyophilised research peptides and small molecules generally, though it’s worth noting 5-Amino-1MQ’s handling differs slightly given it isn’t a peptide. Unreconstituted MOTS-c and AOD-9604 should be kept refrigerated at approximately 2-8°C, protected from light in their original sealed vials, and kept free of moisture — premature exposure to humidity before reconstitution is one of the more common, avoidable causes of degradation in short peptides. Once reconstituted with bacteriostatic water, both peptides should remain refrigerated and be used within the supplier’s stated window, typically measured in weeks.

5-Amino-1MQ, supplied as a stable small-molecule powder rather than a lyophilised peptide, is generally more tolerant of room-temperature storage in its unreconstituted form, though refrigerated storage away from light and moisture remains the more conservative and recommended approach for maintaining long-term stability. As with any lyophilised compound, diluent should be added gently against the inside wall of the vial rather than directly onto the powder, and the vial swirled rather than shaken during reconstitution to avoid mechanical stress on the peptide structure where applicable.

Manufactured and Tested to a Consistent Standard

A three-compound bundle raises the stakes on manufacturing consistency in a way a single peptide doesn’t — a researcher running a protocol across all three needs confidence that every vial in the set meets the same purity and identity standard, not just the one they happen to check first. Crown Peptides tests every batch of MOTS-c, 5-Amino-1MQ, and AOD-9604 for HPLC purity and mass spectrometry identity confirmation, with a batch-specific certificate of analysis provided for every order — including bundle orders, where each of the three vials carries its own individual COA rather than a single blanket document covering all three.

That matters especially for MOTS-c and AOD-9604 given their length and structural complexity relative to shorter peptides — a 16-amino-acid chain carries considerably more opportunity for truncated or incorrectly sequenced synthesis by-products than a three- or four-residue peptide, which makes independent purity and identity verification a genuinely meaningful quality check rather than a formality. The full Metabolism & Energy Research Bundle is available directly from Crown Peptides, alongside the complete Crown Peptides catalogue of individually tested research compounds. Researchers wanting more detail on any single compound in the bundle can also read the dedicated guides for MOTS-c, 5-Amino-1MQ, and AOD-9604.

Common Questions About the Bundle

Has this three-compound combination itself been tested in a published study?

No. Each compound’s cell-culture, rodent, or (for AOD-9604) early-phase human data comes from separate research programmes studying that compound individually. The bundle groups them by mechanistic complementarity across the energy-production, fat-storage, and fat-release stages of the same pathway — it isn’t a claim that a combination trial exists.

Is 5-Amino-1MQ a peptide like the other two compounds in the bundle?

No — it’s a small-molecule enzyme inhibitor, not a peptide. It’s grouped with MOTS-c and AOD-9604 because its research role sits on the same metabolic pathway, not because it shares their chemistry.

Which of the three has the most human data behind it?

AOD-9604, by a clear margin. It progressed to Phase II human obesity trials in the early 2000s, giving it more clinical-stage history than either MOTS-c or 5-Amino-1MQ, both of which remain at the cell-culture and rodent stage of research to date.

Why does the identity table list 5-Amino-1MQ’s molecular weight as unconfirmed?

Because published sources for its CAS number and its molecular weight/formula data didn’t consistently agree on which salt form was being described. Rather than publish a figure that couldn’t be independently confirmed, that row was left out — the CAS number and cation formula shown are the values that checked out consistently across sources.

Where This Leaves the Research

Three compounds, three mechanisms, one metabolic pathway covered from mitochondrial output through to fat release — that’s the entire premise behind studying MOTS-c, 5-Amino-1MQ, and AOD-9604 alongside each other. Each one brings its own decade-plus of independent research: MOTS-c’s AMPK-driven metabolic story now extending into diabetic cardiac tissue a decade after its discovery, 5-Amino-1MQ’s NNMT-blocking mechanism reaching into gut microbiome composition as well as adipose tissue, and AOD-9604’s fragment-engineering approach carrying it further into human trials than almost anything else in this catalogue. Researchers designing protocols around any one piece of that pathway now have a reason to look at the other two as well — not because the combination has been proven, but because the mechanistic map is genuinely complementary and worth exploring further. The bundle is there for exactly that kind of research question.

References

1. Lee C, Zeng J, Drew BG, et al. The mitochondrial-derived peptide MOTS-c promotes metabolic homeostasis and reduces obesity and insulin resistance. Cell Metab. 2015;21(3):443-454. https://pubmed.ncbi.nlm.nih.gov/25738459/
2. Mitochondria-derived peptide MOTS-c restores mitochondrial respiration in type 2 diabetic heart. Front Physiol. 2025. https://doi.org/10.3389/fphys.2025.1602271
3. Neelakantan H, Vance V, Wetzel MD, et al. Selective and membrane-permeable small molecule inhibitors of nicotinamide N-methyltransferase reverse high fat diet-induced obesity in mice. Biochem Pharmacol. 2018;147:141-152. https://pubmed.ncbi.nlm.nih.gov/29155147/
4. Reduced calorie diet combined with NNMT inhibition establishes a distinct microbiome in DIO mice. Sci Rep. 2022. https://pubmed.ncbi.nlm.nih.gov/35013352/
5. Ng FM, Sun J, Sharma L, Libinaka R, Jiang WJ, Gianello R. Metabolic studies of a synthetic lipolytic domain (AOD9604) of human growth hormone. Horm Res. 2000;53(6):274-278. https://pubmed.ncbi.nlm.nih.gov/11146367/
6. Increase of fat oxidation and weight loss in obese mice caused by chronic treatment with human growth hormone or a modified C-terminal fragment. Int J Obes Relat Metab Disord. 2001. https://pubmed.ncbi.nlm.nih.gov/11673763/